Abstract
Cancer patients with haematological malignancies are at risk for chronic hepatitis E virus infection following chimeric antigen receptor (CAR) T-cell therapy. Strong clinical suspicion is essential for the early diagnosis and prompt treatment of this difficult-to-treat type of viral hepatitis. Commentary on: Schwarz et al. Chronic hepatitis E in a patient after CAR-T cell treatment for diffuse large B-cell lymphoma and rapid progression towards decompensated liver cirrhosis. Br J Haematol 2024 (Online ahead of print). doi: 10.1111/bjh.19892.
Original language | English (US) |
---|---|
Journal | British Journal of Haematology |
DOIs |
|
State | Accepted/In press - 2024 |
Keywords
- CAR T-cell therapy
- chronic hepatitis E virus
- hematologic malignancies
- ribavirin
ASJC Scopus subject areas
- Hematology